METTL7B

Across TCGA pan-cancer cohorts, METTL7B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated METTL7B data layer compared with 31 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher METTL7B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated METTL7B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where METTL7B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	33	view →
PDAC	OS	Tertile	II,III,IV	0.713	0.408	<.001	16	view →
LUAD	DFS	Tertile	III,IV	0.599	0.993	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

METTL7B–CCRCC (DFS)

Open the CCRCC breakdown →